Xenon Pharmaceuticals Inc.
XENENASDAQHealthcareBiotechnology
As of Oct 15, 2026 close
- Market cap
- $3.42B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $33.52$72.66
- Volume (live)
- -
- Avg. volume (3M)
- 2.28M
Xenon Pharmaceuticals (XENE) Stock Price & Financial Analysis
Xenon Pharmaceuticals Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $33.99 - $34.99 |
|---|---|
| 52-Week High | $72.66 |
| 52-Week Low | $33.52 |
| Open | $34.11 |
| Volume (last close) | 1.62M |
| Average Volume (3M) | 2.28M |
| 50-Day MA | $51.93 |
|---|---|
| 200-Day MA | $52.76 |
| 1-Year Change | −18.59% |
| Market Cap | 3.42B |
|---|---|
| Shares Outstanding | 99.61M |
| Price to Book (P/B) | 2.75 |
| EV/EBITDA | -7.72 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 15, 2026. Data sources and methodology
Xenon Pharmaceuticals at a Glance
As of the Oct 15, 2026 close, Xenon Pharmaceuticals (XENE) has a market capitalization of $3.42B. Revenue fell 100.0% year over year.
As of its latest reported balance sheet, it holds $119.53M in cash and securities against $6.42M of debt, a net cash position of $113.11M.
Xenon Pharmaceuticals does not currently pay a dividend.
The share price is down 18.6% over the past year. At $34.33 (the Oct 15, 2026 close) it sits near the bottom of its 52-week range of $33.52 to $72.66, below its 200-day moving average of $52.76.
Based on 17 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $70.00, 103.9% above the Oct 15, 2026 close.
Frequently Asked Questions About Xenon Pharmaceuticals
What is the current stock price for XENE?
As of the Oct 15, 2026 close, XENE stock trades at $34.33. The 52-week range is $33.52–$72.66, with a day range of $33.99–$34.99.
What is the P/E ratio for XENE?
The P/E ratio (Price-to-Earnings) for XENE is shown in the Key Statistics section. This valuation metric helps compare Xenon Pharmaceuticals Inc. to industry peers.
Does XENE pay dividends?
Xenon Pharmaceuticals does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for XENE?
Based on ratings from 17 professional analysts over the last 90 days, the consensus for XENE is Buy. The average 12-month price target is $70.00, a 103.9% upside from the Oct 15, 2026 close of $34.33.
What is the market cap of XENE?
As of the Oct 15, 2026 close, Xenon Pharmaceuticals's market capitalization is $3.42B, classifying it as a mid-cap company. Xenon Pharmaceuticals operates in the Healthcare sector within the Biotechnology industry.